Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis Bone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend …

#PEACE3 confirmed efficacy of combo of #Enzalutamide & #Ra223. For any treatment, safety & toxicity equally important. Read our recommendations on use of bone protection @eortc.bsky.social @mcrcnews.bsky.social @ccparker.bsky.social
👇🏽👇🏽👇🏽👇🏽👇🏽👇🏽👇🏽
www.sciencedirect.com/science/arti...